Schwab Charles Investment Management Inc. acquired a new stake in Nymox Pharmaceutical Corporation (NASDAQ:NYMX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 50,400 shares of the biopharmaceutical company’s stock, valued at approximately $222,000. Schwab Charles Investment Management Inc. owned approximately 0.10% of Nymox Pharmaceutical Corporation at the end of the most recent reporting period.

Nymox Pharmaceutical Corporation (NASDAQ NYMX) opened at $3.47 on Monday. Nymox Pharmaceutical Corporation has a 52 week low of $2.67 and a 52 week high of $5.10. The company has a debt-to-equity ratio of 61.64, a current ratio of 1.44 and a quick ratio of 1.42.

Separately, ValuEngine lowered Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Want to see what other hedge funds are holding NYMX? Visit to get the latest 13F filings and insider trades for Nymox Pharmaceutical Corporation (NASDAQ:NYMX).

Institutional Ownership by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with's FREE daily email newsletter.